Table 5.
Correlation between Zinc intake and status values with plasma PUFA profile and estimated desaturase activity in hemodialysis patients.
| LA | ALA | DGLA | AA | EPA | DHA | n-6/n-3 |
EPA +
DHA |
D5D | D6D |
LA /
DGLA |
SCD16 | SCD18 | ELO | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| r | 0.173 | 0.213 | 0.133 | 0.023 | 0.026 | −0.048 | 0.007 | 0.058 | −0.092 | 0.011 | −0.025 | −0.036 | 0.054 | 0.073 |
| p | 0.284 | 0.182 | 0.406 | 0.892 | 0.874 | 0.742 | 0.955 | 0.729 | 0.564 | 0.947 | 0.883 | 0.827 | 0.761 | 0.668 |
| Serum | ||||||||||||||
| Zn | ||||||||||||||
| r | −0.125 | −0.218 | 0.357 | 0.250 | −0.292 | −0.052 | 0.165 | −0.112 | −0.168 | 0.331 | −0.335 | −0.229 | −0.183 | 0.220 |
| p | 0.442 | 0.174 | 0.024 | 0.118 | 0.064 | 0.748 | 0.307 | 0.491 | 0.296 | 0.037 | 0.033 | 0.155 | 0.277 | 0.168 |
| Serum | ||||||||||||||
| Cu | ||||||||||||||
| r | −0.032 | −0.147 | 0.256 | 0.089 | −0.465 | 0.079 | 0.060 | −0.027 | −0.215 | 0.181 | −0.202 | 0.165 | −0.202 | 0.575 |
| p | 0.842 | 0.365 | 0.111 | 0.583 | 0.003 | 0.627 | 0.704 | 0.868 | 0.184 | 0.263 | 0.211 | 0.310 | 0.211 | <0.001 |
| Cu/Zn | ||||||||||||||
| r | 0.118 | 0.021 | −0.023 | −0.118 | −0.364 | 0.093 | −0.060 | 0.036 | −0.087 | −0.070 | 0.063 | 0.035 | −0.027 | 0.384 |
| p | 0.470 | 0.899 | 0.907 | 0.470 | 0.090 | 0.566 | 0.715 | 0.827 | 0.589 | 0.666 | 0.697 | 0.829 | 0.867 | 0.014 |
LA, linoleic acid; DGLA, dihomo-γ-linolenic acid; AA, arachidonic acid; ALA, alfa-linolenic acid; EPA, eicosapentaenoic acid, DHA, docosahexaenoic acid; D5D, Δ-5-desaturase; AA/DGLA (20:4 n-6/20:3 n-6); D6D, Δ-6-desaturase; DGLA/LA (20:3 n-6/18:2 n-6); SCD16 and 18, stearoil-CoA desaturase 16 and 18; ELO, (DPAn-3/EPA).